Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings West Pharmaceutical Services, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: West Pharmaceutical Services, Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: West Pharmaceutical Services, Inc.
  • With an expected P/E ratio at 35.39 and 31.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Rating Financials

West Pharmaceutical Services, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

West Pharmaceutical Services, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

West Pharmaceutical Services, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

West Pharmaceutical Services, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

West Pharmaceutical Services, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
1.75TCr
AA
20TCr
BBB
13TCr
BBB
7TCr
AA
6.17TCr
AAA
4.89TCr
BBB
3.77TCr - - - - - - -
2.66TCr
BBB
2.4TCr
AAA
2.07TCr
A
Average 6.32TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Equities
  3. WST Stock
  4. Ratings West Pharmaceutical Services, Inc.